“…Targeting the Nrf2 pathway with small-molecule activators presents an attractive opportunity because the target is an intrinsic cellular pathway that is designed to be dynamically modulated. The need for this type of therapy in MS is clear, because current evidence indicates free radicals play a large role in MS pathogenesis (van Horssen et al, 2011), with damage to protein, lipid, and DNA in the tissues and cells proximal to lesion areas and in circulation (Vladimirova et al, 1998;Ferretti et al, 2005;van Horssen et al, 2008). It is noteworthy that these studies have shown that some antioxidant response proteins, including Nrf2, are elevated in MS lesions (van Horssen et al, 2008(van Horssen et al, , 2010; however, the degree of intrinsic antioxidant induction is apparently insufficient to ultimately prevent disease progression.…”